High-Risk Anal Cancer: Predictive Value of ZNF582 & ASCL1 Methylation

Congratulations to Valentine Ferre, Charlotte Charpentier, Laurent Abramowitz and co-authors on publishing their article in eBioMedicine!

The study shows that higher methylation levels of ZNF582 and ASCL1 on anal smears — measured with Self-screen PreCursor-M AnoGYN Methylation Assay (RUO) — are strongly predictive of progression to anal cancer in high-risk patients, with performance exceeding cytology, HPV and p16/Ki67 testing.

We’re proud to see our AnoGYN methylation assay featured in this study.

This is an important step toward more effective triage strategies and preventing overtreatment and high-resolution anoscopy consultation overload.

Read the full article here: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00380-9/fulltext?rss=yes